Pharma giant AstraZeneca was among London’s biggest losers ... including one count of stealing €500,000 from Bank of Ireland ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

The decision by the court to pause the cap coming into effect is a welcome first step in this process that recognises the ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

The U.K. pharmaceutical company AstraZeneca has become the largest multinational drugmaker in China, drawing 13% of its $5.8 billion in revenue last year from there, against a backdrop of an acute ...

BEIJING—An investigation involving a top executive at drugmaker AstraZeneca AZN-1.36%decrease; red down pointing triangle is the latest to rattle foreign companies in China, where a series of ...

The trial has shown that treatment can "achieve control of the disease but not a cure," Carel le Roux, MD, PhD, of University ...

The president of AstraZeneca’s China division has been placed under investigation by local police, as Beijing advances an anti-corruption crackdown in the healthcare sector. The British ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.